U.S. flag

An official website of the United States government

NM_000527.5(LDLR):c.1729T>C (p.Trp577Arg) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jul 6, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002411087.2

Allele description [Variation Report for NM_000527.5(LDLR):c.1729T>C (p.Trp577Arg)]

NM_000527.5(LDLR):c.1729T>C (p.Trp577Arg)

Gene:
LDLR:low density lipoprotein receptor [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
19p13.2
Genomic location:
Preferred name:
NM_000527.5(LDLR):c.1729T>C (p.Trp577Arg)
Other names:
NP_000518.1:p.W577R
HGVS:
  • NC_000019.10:g.11116882T>C
  • NG_009060.1:g.32502T>C
  • NM_000527.5:c.1729T>CMANE SELECT
  • NM_001195798.2:c.1729T>C
  • NM_001195799.2:c.1606T>C
  • NM_001195800.2:c.1225T>C
  • NM_001195803.2:c.1348T>C
  • NP_000518.1:p.Trp577Arg
  • NP_000518.1:p.Trp577Arg
  • NP_001182727.1:p.Trp577Arg
  • NP_001182728.1:p.Trp536Arg
  • NP_001182729.1:p.Trp409Arg
  • NP_001182732.1:p.Trp450Arg
  • LRG_274t1:c.1729T>C
  • LRG_274:g.32502T>C
  • LRG_274p1:p.Trp577Arg
  • NC_000019.9:g.11227558T>C
  • NM_000527.4:c.1729T>C
  • c.1729T>C
Protein change:
W409R
Links:
LDLR-LOVD, British Heart Foundation: LDLR_000802; dbSNP: rs879255000
NCBI 1000 Genomes Browser:
rs879255000
Molecular consequence:
  • NM_000527.5:c.1729T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195798.2:c.1729T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195799.2:c.1606T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195800.2:c.1225T>C - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001195803.2:c.1348T>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002716700Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Jul 6, 2021)
germlineclinical testing

PubMed (13)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Homozygous familial hypercholesterolemia: A novel point mutation (W556R) in a Turkish patient.

Gutierrez G, Schneider A, Jobs J, Schmidt H, Korte A, Manns MP, Stuhrmann M.

Hum Mutat. 2000 Oct;16(4):374. No abstract available.

PubMed [citation]
PMID:
11013454

The molecular basis of familial hypercholesterolemia in The Netherlands.

Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP.

Hum Genet. 2001 Dec;109(6):602-15. Epub 2001 Nov 9.

PubMed [citation]
PMID:
11810272
See all PubMed Citations (13)

Details of each submission

From Ambry Genetics, SCV002716700.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (13)

Description

The p.W577R pathogenic mutation (also known as c.1729T>C), located in coding exon 12 of the LDLR gene, results from a T to C substitution at nucleotide position 1729. The tryptophan at codon 577 is replaced by arginine, an amino acid with dissimilar properties. This alteration, also referred to as p.W556R, has been reported in both the homozygous and heterozygous states in multiple Turkish families with familial hypercholesterolemia (FH) and was found to segregate with the disease (Gutierrez G et al. Hum. Mutat., 2000 Oct;16:374; Sözen MM et al. Atherosclerosis, 2005 May;180:63-71; Schmidt HH et al. Clin Transplant, 2008 Mar-Apr;22:180-4; Schaefer JR et al. Clin Res Cardiol Suppl, 2012 Jun;7:2-6; Taylan C et al. J Clin Lipidol 2016 Aug;10:1303-1310). This alteration was also described in association with FH in other populations (Fouchier SW et al. Hum. Genet., 2001 Dec;109:602-15; Amsellem S et al. Hum. Genet., 2002 Dec;111:501-10; Leren TP et al. Semin Vasc Med, 2004 Feb;4:75-85; Widhalm K et al. J. Inherit. Metab. Dis., 2007 Apr;30:239-47; Fairoozy RH et al. Sci Rep, 2017 Dec;7:17087). Internal analysis has predicted that this alteration, located in the YWTD motif of LDLR class B report 5, disrupts the protein structure (Lo Surdo P et al. EMBO Rep., 2011 Dec;12:1300-5; Etxebarria A et al. Hum. Mutat., 2015 Jan;36:129-41). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024